Tenaya Therapeutics’ TN-201 demonstrates tolerability and protein expression in early HCM trial

Tenaya Therapeutics, a clinical-stage biotechnology company, has released promising interim results from its MyPEAK-1 Phase 1b/2 clinical trial evaluating TN-201 gene therapy for MYBPC3-associated hypertrophic ... Read More